Soluble programmed death‐1 is a useful indicator for mortality in patients with adult‐onset Still's disease.

This article discusses a study that examines the potential use of soluble programmed death 1 (sPD-1) as a biomarker for predicting mortality in patients with adult-onset Still's disease (AOSD). AOSD is a systemic inflammatory disease with a varied clinical course, and currently, there are no established biomarkers for predicting prognosis. The study included 69 patients with AOSD and found that higher levels of sPD-1 were associated with worse survival outcomes. The authors suggest that sPD-1 could be a valuable indicator for mortality in patients with AOSD. However, further research is needed to confirm the usefulness of sPD-1 levels as an indicator of diagnosis and disease activity in AOSD patients. [Extracted from the article]